Transgene Provides Business and Financial Update for Q1 2025

TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025 Dr. Simone Steiner appointed Chief Technical Officer (CTO) Business funded until the end of April 2026 Strasbourg, France, April 24, 2025, 5:45 p.m. CET –Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer,today provides abusiness update,including itsfinancial positionas of March 31, 2025. Key...

Illkirch Graffenstaden, 24/04/2025 (informazione.news - comunicati stampa - economia)

Dr. Simone Steiner appointed Chief Technical Officer (CTO) 

Business funded until the end of April 2026

Strasbourg, France, April 24, 2025, 5:45 p.m. CET – today provides a , as of March 31, 2025.

Over the first quarter of 2025, all of Transgene's preclinical and clinical assets progressed in line with expectations.

Transgene will deliver a on , its lead individualized neoantigen therapeutic cancer vaccine based on its ® platform and powered by NEC's AI technologies, at the ( ) annual meeting in Chicago (USA).
This oral presentation, which will take place on June 1, 2025, is part of a session that highlights clinical data that stood out among many submissions.
The updated data will include as adjuvant treatment for head and neck cancer.

As the treatment landscape evolves, these updated clinical data in the adjuvant treatment of operable head and neck cancer will be instrumental in determining TG4050's optimal development path towards registration in this indication.

In the Phase II part of the trial, .

The ® individualized cancer vaccine platform can be applied across a range of solid tumors where in many cases a significant unmet medical need remains. Consequently, Transgene is starting initial preparations for a in a second undisclosed indication in an early treatment setting, .

The Company will present a poster on clinical data from the randomized Phase II trial of TG4001 in combination with avelumab in HPV16-positive recurrent/metastatic anogenital and cervical cancer at ASCO. While the primary endpoint of the Phase II study was not met, positive signals in the cervical cancer subgroup have been observed and further details will be included in the poster presentation.

The abstracts will be available on the ASCO website on May 22, 2025, at 5 p.m. ET.

She is responsible for manufacturing and process development for Transgene's innovative immunotherapy product pipeline and leads the optimization of the manufacturing process for individualized neoantigen therapeutic vaccines. She is also involved in the development of potential new candidates based on the ® platform, as well as in planning potential future clinical studies.

Dr. Steiner reports to Chairman and CEO, Alessandro Riva, and is a member of the Executive Committee.

During the first quarter of 2025, operating revenue mostly comprised Research Tax Credit of 2.3 million compared to €1.6 million for the same period in 2024. This increase reflects the progress of the ongoing Phase II part of the clinical trial evaluating TG4050 in head and neck cancer.

compared to €16.7 million as of December 31, 2024. In the first quarter of 2025, Transgene's net cash burn was €14.8 million compared to €11.2 million for the same period in 2024. This results from progress in the Phase II part of the trial evaluating TG4050 in head and neck cancer, with sustained patient enrollment and related expenses, including the manufacturing of individualized batches.

The Company has drawn down €22.5 million from this facility as of March 31, 2025.

, enabling the Company to reach important development milestones and deliver significant news flow on its portfolio.

***

myvac®
myvac® myvac

Attachment